• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 5. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312

Chemical Compound CAS No. 1216132-36-3: (3-Methylimidazo[1,2-a]pyridin-6-yl)methanamine Dihydrochloride

The compound with CAS No. 1216132-36-3, commonly referred to as (3-Methylimidazo[1,2-a]pyridin-6-yl)methanamine Dihydrochloride, is a significant molecule in the field of organic chemistry and pharmacology. This compound has garnered attention due to its unique structural properties and potential applications in drug development. The imidazo[1,2-a]pyridine core of the molecule is a key feature, contributing to its stability and reactivity. Recent studies have highlighted its role in various biological systems, making it a subject of interest for researchers worldwide.

Imidazo[1,2-a]pyridine derivatives are known for their diverse biological activities, including anti-inflammatory, antioxidant, and neuroprotective effects. The methyl group substitution at the 3-position of the imidazo[1,2-a]pyridine ring enhances the compound's lipophilicity, which is crucial for its bioavailability and pharmacokinetic properties. This modification also plays a pivotal role in modulating the compound's interaction with biological targets, such as enzymes and receptors.

The dihydrochloride salt form of this compound ensures its solubility in aqueous solutions, making it suitable for various experimental setups and potential therapeutic applications. Recent research has focused on its ability to inhibit specific kinases involved in inflammatory pathways, suggesting its potential as an anti-inflammatory agent. Additionally, studies have explored its role in modulating neurotransmitter systems, highlighting its potential in neurodegenerative disease treatment.

From a synthetic perspective, the preparation of (3-Methylimidazo[1,2-a]pyridin-6-yl)methanamine Dihydrochloride involves a multi-step process that includes cyclization reactions and functional group transformations. The synthesis begins with the formation of the imidazo[1,2-a]pyridine ring system through a condensation reaction between an appropriate amine and a carbonyl compound. Subsequent methylation and amidation steps are then employed to introduce the methyl group and methanamine functionality, respectively.

The dihydrochloride salt is typically obtained by protonating the amine group with hydrochloric acid under controlled conditions. This process ensures the formation of a stable salt form that is ideal for both analytical characterization and biological testing. Advanced analytical techniques such as NMR spectroscopy and mass spectrometry have been employed to confirm the structure and purity of this compound.

In terms of biological evaluation, (3-Methylimidazo[1,2-a]pyridin-6-yl)methanamine Dihydrochloride has shown promising results in preclinical studies. Its ability to inhibit key enzymes involved in inflammation has been demonstrated in vitro using cell culture models. Furthermore, animal studies have revealed its potential to reduce oxidative stress markers in tissues affected by chronic inflammation.

Recent advancements in computational chemistry have also contributed to understanding the molecular interactions of this compound with biological targets. Molecular docking studies have provided insights into how the methyl group substitution influences binding affinity at specific receptor sites. These findings are crucial for optimizing the compound's pharmacological profile and guiding further drug development efforts.

In conclusion, (3-Methylimidazo[1,2-a]pyridin-6-yl)methanamine Dihydrochloride represents a valuable addition to the arsenal of bioactive compounds being explored for therapeutic applications. Its unique chemical structure and promising biological activities make it a subject of ongoing research interest. As further studies unravel its full potential, this compound holds promise for addressing unmet medical needs in various therapeutic areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)